Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.

In order to determine K(m) values of substrates for CYP3A4-mediated metabolism, an in silico model has been developed in the present work. Using electrotopological state (E-state) indices, together with Bayesian-regularized neural network (BRNN), we have described an in silico method to model log(1/K(m)) values of various substrates. The relative importance of the E-state indices is analyzed by principal component analysis. By using an additional external test set, which is independent of the training set, the robustness and predictivity of the model are also validated.

[1]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[2]  B. Bruguerolle,et al.  Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[3]  R. Branch,et al.  Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[4]  Keli Han,et al.  Structural determinants of steroids for cytochrome P450 3A4-mediated metabolism , 2004 .

[5]  David A Winkler,et al.  Modelling blood-brain barrier partitioning using Bayesian neural nets. , 2004, Journal of molecular graphics & modelling.

[6]  Matej Oresic,et al.  Integrative biological analysis of the APOE*3-leiden transgenic mouse. , 2004, Omics : a journal of integrative biology.

[7]  M. Odomi,et al.  Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation , 1998, European Journal of Clinical Pharmacology.

[8]  F. Gonzalez,et al.  Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. , 1992, Cancer research.

[9]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[10]  S. Wrighton,et al.  In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[11]  L. Benet,et al.  Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[12]  K. Wikvall,et al.  6α-Hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes , 1999 .

[13]  B. K. Park,et al.  Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.

[14]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[15]  K. Chiba,et al.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. , 1998, The Journal of pharmacology and experimental therapeutics.

[16]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[17]  D. Greenblatt,et al.  Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man , 1998, The Journal of pharmacy and pharmacology.

[18]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[19]  D. Greenblatt,et al.  CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[20]  D. Greenblatt,et al.  Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.

[21]  C. Miranda,et al.  Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. , 1991, Carcinogenesis.

[22]  M. Clay,et al.  In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[23]  J. W. Allis,et al.  Kinetics of bromodichloromethane metabolism by cytochrome P450 isoenzymes in human liver microsomes. , 2002, Chemico-biological interactions.

[24]  H. Yamazaki,et al.  Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[25]  T Ishizaki,et al.  Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  R. Obach.  Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[27]  William D. Penny,et al.  An empirical evaluation of Bayesian sampling with hybrid Monte Carlo for training neural network classifiers , 1999, Neural Networks.

[28]  L. Wienkers,et al.  Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[29]  D. Greenblatt,et al.  Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects , 1999, Biological Psychiatry.

[30]  A. D. Rodrigues,et al.  In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[31]  L. Hall,et al.  Molecular Structure Description: The Electrotopological State , 1999 .

[32]  H. Yamazaki,et al.  Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.

[33]  L. Benet,et al.  Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[34]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[35]  Jarmo Huuskonen.  QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..

[36]  D. Flockhart,et al.  Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.

[37]  David J. C. MacKay,et al.  A Practical Bayesian Framework for Backpropagation Networks , 1992, Neural Computation.

[38]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[39]  Lemont B. Kier,et al.  Modeling Blood-Brain Barrier Partitioning Using the Electrotopological State , 2002, J. Chem. Inf. Comput. Sci..

[40]  Geoffrey E. Hinton,et al.  Bayesian Learning for Neural Networks , 1995 .

[41]  Ryo Shoji.  The Potential Performance of Artificial Neural Networks in QSTRs for Predicting Ecotoxicity of Environmental Pollutants , 2005 .

[42]  J. Lasker,et al.  Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[43]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[44]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[45]  T. Koudriakova,et al.  Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents , 1997, Clinical pharmacology and therapeutics.

[46]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[47]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[48]  A. Kalgutkar,et al.  Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[49]  Christopher M. Bishop,et al.  Neural networks for pattern recognition , 1995 .

[50]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[51]  H. Yamazaki,et al.  Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[52]  H. Yamazaki,et al.  A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[53]  A. D. Rodrigues,et al.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[54]  P. Souček,et al.  Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. , 1997, Biochemical pharmacology.

[55]  A. D. Rodrigues,et al.  Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[56]  O. Olesen,et al.  Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[57]  I Skånberg,et al.  In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.

[58]  T. Walle,et al.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.

[59]  D. Greenblatt,et al.  Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.

[60]  M. Hino,et al.  Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[61]  L. Bertilsson,et al.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.

[62]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[63]  J. Halpert,et al.  The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. , 2000, Archives of biochemistry and biophysics.

[64]  S. M. Abel,et al.  Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[65]  L. Benet,et al.  Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. , 1996, Biochemical pharmacology.

[66]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[67]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[68]  D. Greenblatt,et al.  O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants , 1999, Neuropsychopharmacology.

[69]  X. J. Zhou,et al.  Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.

[70]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. , 1996, The Journal of pharmacology and experimental therapeutics.